ProfileGDS5678 / 1431856_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 79% 78% 76% 82% 73% 78% 77% 75% 79% 83% 79% 80% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.581280
GSM967853U87-EV human glioblastoma xenograft - Control 25.6231479
GSM967854U87-EV human glioblastoma xenograft - Control 35.3914278
GSM967855U87-EV human glioblastoma xenograft - Control 45.2418476
GSM967856U87-EV human glioblastoma xenograft - Control 55.9821782
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.5826773
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.2806378
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.2665777
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.0134175
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.5326879
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.0360483
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.5253579
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.6530680
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.618380